

Transplant Creations focuses on development, promotion and implementation of reduced intensity conditioning autologous and allogeneic transplantation early during the disease course to improve disease outcome.

In support of Safety and Efficacy



Transplant Creations

*Service Department
P.O. Box 51342
1007 EH Amsterdam
The Netherlands
P: 0031-6-124 33616
info@transplantcreations.com*

CONSULTING

**IN THE
THERAPEUTIC
AREAS**

**HEMATOPOIETIC
STEM CELL
TRANSPLANTATION**

ONCOLOGY

HEMATOLOGY

DESCRIPTION OF SERVICES

Straightforward product development can be a real challenge. Product characteristics, preclinical data, clinical and regulatory requirements, market potential and development costs should be considered.

Experienced in evaluation of the therapeutic potential of products, we provide advice in strategic planning during the preclinical stage of development, during early or late stage clinical development, or at a moment that companies consider acquisition or development of a product in a therapeutic area within our focus.

Specialized in hematopoietic stem cell transplantation, oncology and hematology, we provide advice in product development and combination product development.

CRO's services can be furnished upon request.

Feel free to contact us to discuss your needs and request further information.

Consulting in Biopharma & Biotech Product Development

- Strategic planning
- Assessment of products for clinical development
- Scientific advice and forecasting.
- Study design en planning of clinical research program
- Assistance in protocol development and clinical program development.
- Assessment of study documentation.
- Advice in Good Clinical Practice
- Market research from clinical perspective
- Product safety assessment and regulatory aspects

FOCUS

Therapeutic areas

- Hematopoietic stem cell transplantation
- Oncology
- Hematology

Products and Procedures

- Drugs
- Biologics
- Device
- Cell therapy
- Program Development with Products

Specific feature

Our clinical research program offers companies to integrate a compound in the upfront therapy. This may involve therapeutic, supportive or prophylactic drugs that have been registered and have a proven safety and efficacy profile.

